Expert panels recommend Bharat Biotech’s Covaxin for phase 2/3 trials on 2-18 year-olds
Trials will take place in 525 subjects at various sites like AIIMS, Delhi, AIIMS, Patna, and Meditrina Institute of Medical Sciences, Nagpur
Subject Expert Committee (SEC) asked the firm to submit the interim safety data of phase II clinical trials
They also have to submit DSMB recommendations to the Central Drugs Standard Control Organisation before proceeding to phase III
Covaxin is indigenously developed by Bharat Biotech in collaboration with ICMR
Bharat Biotech had commenced direct supply of Covaxin to 14 states
